A Multicenter, Open-Label, Randomized Phase Ii Trial Of Adenovirus-Mediated Endostatin Gene Therapy In Combination With Paclitaxel And Cisplatin Chemotherapy In Advanced Head And Neck Carcinoma: Preliminary Results

W. Huang,Wu J,X. Lin,Su Li,R. Liu,W. Hu,Y. Xia,Li Zhang,Wenqi Jiang,Z. Guan
DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.e16005
IF: 45.3
2010-01-01
Journal of Clinical Oncology
Abstract:e16005 Background: E10A is an adenovirus containing human endostatin gene (Ad-rhE). The phase I clinical trial of E10A revealed that weekly intratumoral injection of up to 1 × 1012 VP of E10A to patients with solid tumor is a feasible and well-tolerated procedure that exerts mild antitumor effects. In this trial, we aimed to evaluate the safety and efficacy of E10A combined with paclitaxel/cisplatin chemotherapy in advanced head and neck carcinoma (ClinicalTrials.gov identifier: NCT00634595). Methods: Patients treated with chemotherapy alone were given paclitaxel (160mg/m2 on d1) and cisplatin (25mg/m2 on d1, d2 and d3) every 21 days. Patients in combination group received two intratumral injections of E10A on days 1 and 8, combined with paclitaxel (160mg/m2 on d3) and cisplatin (25mg/m2 on d3, d4 and d5), and then every 21 days as long as no PD or untolerable toxicity occurred. The primary efficacy criterion was response rate (CR/PR) determined in cycle 2 to cycle 4. Patients were assessed for toxicity and viral shedding, and antitumor response was evaluated by imaging techniques and tumor biopsy. Results: As of December 2009, evaluable population included sixty-eight subjects. In combination group, 1/34 (2.9%) had CR and 17/34 (50%) had PR. For patients received chemotherapy alone, 1/34 (2.9%) had CR and 7/34 (20.6%) had PR. The most frequent adverse events associated with E10A were fever and local reaction of injection site, primarily grades 1 and 2. Conclusions: Intratumoral injection of E10A is feasible and well tolerated and shows encouraging antitumor effects. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, GlaxoSmithKline AstraZeneca, Bayer, Novartis, sanofi-aventis
What problem does this paper attempt to address?